Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model
暂无分享,去创建一个
H. Hricak | R. Blasberg | V. Ponomarev | Y. Fong | I. Serganova | P. Zanzonico | S. Cai | C. Riedl | Y. Woo | B. Wen | P. Brader
[1] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[2] David L. Schwartz,et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.
[3] S. Fan,et al. High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis , 2006, Molecular Cancer Therapeutics.
[4] J. Pouysségur,et al. Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.
[5] A. Heerschap,et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. , 2006, International journal of radiation oncology, biology, physics.
[6] N. Petrelli,et al. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Dewhirst,et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. , 2005, Cancer research.
[8] Vladimir Ponomarev,et al. Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.
[9] W. Denny. Prospects for hypoxia-activated anticancer drugs. , 2004, Current Medicinal Chemistry - Anti-Cancer Agents.
[10] A. Giaccia,et al. Hypoxic gene expression and metastasis , 2004, Cancer and Metastasis Reviews.
[11] H. Federoff,et al. Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases , 2004, Annals of surgery.
[12] R. Blasberg,et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[13] O. Greco,et al. Prodrugs in genetic chemoradiotherapy. , 2003, Current pharmaceutical design.
[14] E. Rofstad,et al. Temporal heterogeneity in oxygen tension in human melanoma xenografts , 2003, British Journal of Cancer.
[15] R. Blasberg,et al. Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. , 2003, Neoplasia.
[16] A. Harris,et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.
[17] D. Hedley,et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Koch,et al. Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.
[19] A. Harris,et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.
[20] T. Hunter,et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[21] M. Marangolo,et al. Global approach to hepatic metastases from colorectal cancer: indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments , 2000, Medical oncology.
[22] S M Evans,et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.
[23] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[24] J R Griffiths,et al. The OxyLite: a fibre-optic oxygen sensor. , 1999, The British journal of radiology.
[25] P Vaupel,et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.
[26] C. Koch,et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. , 1996, The Journal of pharmacology and experimental therapeutics.
[27] R. Blasberg,et al. Imaging the expression of transfected genes in vivo. , 1995, Cancer research.
[28] M. Buyse,et al. Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group). , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[29] P. Loehrer. Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon Cancer , 2008 .
[30] A. Giaccia,et al. Hypoxia, gene expression, and metastasis , 2007, Cancer and Metastasis Reviews.
[31] É. Vinet,et al. Regional treatment of metastasis: surgery of colorectal liver metastases. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.